DNA methylation, epigenetic writers/ erasers, translational research, epigenetic biomarkers, epigenetic therapy
cancer cell lines, patient samples (urine, blood, plasma, tissue)
QMSP, Bisulfite sequencing, analysis of histone marks in a cellular context (IHC, WB, ChiP), in vitro proliferation (MTT), apoptosis, Invasion, and wound healing and pharmacological assays, In vitro systems for genetic alterations: siRNA, genetic transfection, tumor and bodily fluids banking.
My lab collaborates with medical doctors (Pathology, Urology, Oncology) for patient material (tissue slice technology), with a lab (QPNA / Dpt Chemistry -Universisty of Aveiro) that performs proteomic analysis [Quantitative proteomics (2D-DIGE, iTRAQ, SILAC) and Posttranslational modifications determination (MALDI-TOF/TOF, LC-ESI, LC-MALDI]. We hold a 40% share in a patent (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1), based in a study from our group in collaboration with the Norwegian Radium Hospital. My group was involved in an international research consortium (as WP member) of a European project (EpiDiaCan-FP7 program).
Carmen Jerónimo obtained her BSc in Biology from the Faculty of Sciences of University of Porto (1994). The Institute of Biomedical Sciences of the same university granted (ICBAS-UP) the MSc in Oncology (1998), the PhD in Biomedical Sciences (2001), with an experimental project at Johns Hopkins University School of Medicine, under the GABBA Programme, and the habilitation for full professor in Molecular Genetics and Pathology (2011). She is currently Investigator/Head of the Cancer Biology & Epigenetics Group at the Research Center of Portuguese Oncology Institute – Porto (IPO-Porto) and Invited Associate Professor with Full Professor Habilitation in Molecular Pathology and Cancer Epigenetics at Biomedical Sciences Institute of University of Porto. Her research interests are focused on the characterization of the epigenome of tumor cells, as well as the identification of functional changes involved in the breakdown of cell epigenetic homeostasis. In the context of Personalized Medicine, she is especially interested in the development of new of cancer epigenetic biomarkers and drugs for cancer based on the modulation of cancer-related epigenetic aberrations. At present, her research group includes a senior researcher (MD, PhD), two post-docs, five PhD students and five Master students. She has supervised 2 PhD students and co-supervised 3 PhD students, as well as 19 master students and several undergraduate students. Group members hold a 40% share of a patent (US 20130210011/ EP 2630261 A1/ WO 2012052844 A1) based in a study performed in collaboration with the Norwegian Radium Hospital. As scientific leader, she has participated in an international project funded by European Commission, within the Seventh Framework Programme (EpiDiaCan) and the several nationally wide funded projects (FCT, Calouste Gulbenkian Foundation and LPCC-NRN). To the present date, she has authored or co-authored more than 80 international scientific publications including two book chapters and several review articles. She serves as Associate Editor of BMC Cancer and Clin Epigenetics and acts as reviewer of several scientific journals including European Urology, Molecular Carcinogenesis, Neoplasia, Oncotarget, Plos One, Expert Reviews and Epigenetics as well as Grant reviewer [Cancer Research of United Kingdom (2007);, Swiss National Science Foundation (2011); WILLIAMS BARKER BEQUEST: CANCER RESEARCH-Medical Research Foundation, UK (2012); Swiss League Against Cancer (2013); The Czech Science Foundation – GACR (2013);EU_COST OC-2014; PROSTATE CANCER UK (2014); Swiss League Against Cancer (2015); FWF Austrian Science Fund [Clinical Research (KLIF) call(2015); Cancer Research of United Kingdom (2015)] Currently, she is also a member of the following Research Societies: AACR, EACR, SPGH and ASPIC (Portuguese Association for Cancer Research).
Associate editor: BMC Cancer & Clinical Epigenetics,